ARWR compared with GPCR: revenue, margins and what each company keeps, and the suppliers and customers both name

ARWRArrowhead Pharmaceuticals, Inc.

Mkt capRevenueRevenue

GPCRStructure Therapeutics Inc.

Mkt capRevenueRevenue

Compare

ARWRArrowhead Pharmaceuticals, Inc.

GPCRStructure Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ARWR 4

AMGNAmgencustomer

SRPTSarepta Therapeuticscustomer

NVSNovartis Pharmacustomer

—Takeda Pharmaceuticalunlistedcustomer

Shared 0

No disclosed counterparties: GPCR.

Only GPCR 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

ARWRArrowhead Pharmaceuticals, Inc.

60.49· pre 59.64· delayed

Mkt cap$8.5BRevenue$75MQ3 FY26Revenue$829MFY25

GPCRStructure Therapeutics Inc.

21.89· pre 22.41· delayed

Pre-marketOct 30 '26delayed

Mkt cap$4.8BRevenue—Revenue—

Compare

Pre-marketOct 30 '26delayed

ARWRArrowhead Pharmaceuticals, Inc.

GPCRStructure Therapeutics Inc.

60.49pre 59.64delayed

Price

21.89pre 22.41delayed

$8.5B

Mkt cap

$4.8B

Q3 FY26$75M

Revenue

—

FY25$829M

Revenue

—

ARWR60.49vsGPCR21.89Pre-marketOct 30 '26delayed